FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 339:1940-1941 December 24, 1998 Number 26 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Diel, I. J.

To the Editor: In their interesting study, Diel et al. (Aug. 6 issue)¹ demonstrate the efficacy of clodronate therapy when it is used in addition to standard systemic therapy in high-risk patients with early-stage breast cancer. However, it is unclear whether all patients will benefit from this therapy. Although the authors state that in their study, "all the women . . . had a high risk of distant metastases, as indicated by the presence of tumor cells in the bone marrow" and the presence of tumor cells in the bone marrow was associated with "unfavorable prognostic factors," only a minority . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.